WithdrawnNo phase
Observational, Real-life, Retrospective, Data Collection, Use Sibutramine/topiramate in Overweight Comorbidities/obesity
Key facts
- Who runs it
- Eurofarma Laboratorios S.A.
- Where
- Brazil2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Dec 2024
- Ended
- 1 Dec 2025
- Type of study
- Observational
- Treatments tested
- Source document data collection
- Record updated
- 28 February 2025
- Why it stopped
- The study was withdrawn following a thorough evaluation of the current scientific landscape and ongoing advancements in the field. This decision was made to ensure that the research remains aligned with the highest standards of innova
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult patients
- Both sexes
- Diagnose of overweight with comorbidity(ies) or obesity
- Treatment use of sibutramine combined with topiramate
- Treatment prescription between 2011 and the beginning of the study
Who cannot take part
- Individual use of one of the medications (sibutramine or topiramate)
- Use of topiramate for other condition besides overweight with comorbidity(ies) or obesity
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
An observational, multicenter, national study with retrospective real-life data collection on the combined treatment of sibutramine and topiramate (off-label use) for the treatment of overweight with comorbidity(ies) or obesity. Data from all adult patients, of both sexes, for whom combination treatment with sibutramine and topiramate, both at any dose/dosage, were prescribed between the year 2011 and the beginning of the study will be included in the study.
Treatments tested
- Source document data collection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Observational, Multicenter, National Study with Real-life Retrospective Data Collection on the Combined Use of Sibutramine and Topiramate As Anti-obesity Treatment in Overweight Patients with Comorbidity(ies) or Obesity.
- Record updated
- 28 February 2025